LNO-M03

LNO-M03 is a preclinical-stage therapeutic candidate being developed by Linno Pharmaceuticals (also known as Lingnuo Pharmaceuticals). According to company pipeline documentation, the LNO-M03 identifier is associated with two distinct programs: an mRNA-based therapy for the treatment of rare diseases and a monoclonal antibody (mAb) for autoimmune diseases. The 'M' prefix in the sponsor's nomenclature typically designates assets derived from their mRNA technology platform. As of 2024, the specific biological targets and the exact indications within the rare disease and autoimmune categories have not been publicly disclosed. Both programs are currently in the preclinical phase of development.